|
|
Haorui supplies
Amifostine API
(Active Pharmaceutical Ingredient) to pharmaceutical
industry.
Haorui's
Amifostine API
is produced by
FDA approved cGMP facilities,
we supply Amifostine API from small
R&D to large commercial quantity. For product and supply
details please contact us. |
|
Amifostine
Patents 5 |
|
Amifostine Clinical Trials 1
Amifostine Clinical Trials 2 |
|
Amifostine Patents 1
Amifostine Patents 2
Amifostine Patents 3 |
|
Amifostine Patents 4
Amifostine Patents 5 |
| 201 |
6,495,544 |
Homoiminopiperidinyl hexanoic acid inhibitors of
inducible nitric oxide synthase |
| 202 |
6,495,129 |
Methods of inhibiting hematopoietic stem cells using
human myeloid progenitor inhibitory factor-1
(MPIF-1) (Ckbeta-8/MIP-3) |
| 203 |
6,492,390 |
Substituted benzopyran analogs for the treatment of
inflammation |
| 204 |
6,489,312 |
Pharmaceutical formulations comprising aminoalkyl
phosphorothioates |
| 205 |
6,471,943 |
Formulation and method for treating neoplasms by
inhalation |
| 206 |
6,469,040 |
Method of using cyclooxygenase-2 inhibitors in the
treatment and prevention of neoplasia |
| 207 |
6,465,686 |
Halogenated 2-amino-5,6 heptenoic acid derivatives
useful as nitric oxide synthase inhibitors |
| 208 |
6,465,518 |
Halogenated 2-amino-4, 5 heptenoic acid derivatives
useful as nitric oxide synthase inhibitors |
| 209 |
6,462,017 |
Method of reducing side effects of chemotherapy in
cancer patients |
| 210 |
6,426,366 |
Pharmaceutical compositions comprising tyrphostins
|
| 211 |
6,423,734 |
Method of preventing cancer
|
| 212 |
6,419,901 |
Method for treating neoplasms by inhalation
|
| 213 |
6,419,900 |
Formulation and method for treating neoplasms by
inhalation |
| 214 |
6,417,160 |
Methods for increasing schwann cell survival
|
| 215 |
6,409,990 |
Macromolecular carrier for drug and diagnostic agent
delivery |
| 216 |
6,407,278 |
Stable amorphous amifostine compositions and methods
for the preparation and use of the same |
| 217 |
6,403,830 |
Amidino compound and salts thereof useful as nitric
oxide synthase inhibitors |
| 218 |
6,384,259 |
Stable amorphous amifostine compositions and dosage
form |
| 219 |
6,348,209 |
Formulation and method for treating neoplasms by
inhalation |
| 220 |
6,331,289 |
Targeted diagnostic/therapeutic agents having more
than one different vectors |
| 221 |
6,319,682 |
Methods and systems for assessing biological
materials using optical and spectroscopic detection
techniques |
| 222 |
6,309,663 |
Triglyceride-free compositions and methods for
enhanced absorption of hydrophilic therapeutic
agents |
| 223 |
6,303,628 |
Bicycliccarbonyl indole compounds as
anti-inflammatory/analgesic agents |
| 224 |
6,294,558 |
Sulfonylbenzene compounds as
anti-inflammatory/analgesic agents |
| 225 |
6,277,878 |
Substituted indole compounds as anti-inflammatory
and analgesic agents |
| 226 |
6,274,635 |
Alkylated resorcinol derivatives for the treatment
of immune diseases |
| 227 |
6,271,253 |
Substituted benzopyran derivatives for the treatment
of inflammation |
| 228 |
6,267,957 |
Attaching agents to tissue with transglutaminase and
a transglutaminase substrate |
| 229 |
6,265,427 |
Pharmaceutical composition for the method of
treating leukemia |
| 230 |
6,264,917 |
Targeted ultrasound contrast agents
|
| 231 |
6,261,537 |
Diagnostic/therapeutic agents having microbubbles
coupled to one or more vectors |
| 232 |
6,248,363 |
Solid carriers for improved delivery of active
ingredients in pharmaceutical compositions |
| 233 |
6,239,119 |
Topical administration of amifostine and related
compounds |
| 234 |
6,225,325 |
Use of alkylated iminosugars to treat multidrug
resistance |
| 235 |
6,224,903 |
Polymer-lipid conjugate for fusion of target
membranes |
| 236 |
6,218,377 |
Methods for the administration of amifostine and
related compounds |
| 237 |
6,127,351 |
Method for the administration of amifostine and
related compounds |
| 238 |
6,096,339 |
Dosage form, process of making and using same
|
| 239 |
6,080,877 |
Taxanes |
| 240 |
6,077,850 |
Substituted benzopyran analogs for the treatment of
inflammation |
| 241 |
6,075,053 |
Method of reducing or reversing neuropathy
|
| 242 |
6,066,668 |
Formulations and methods of reducing toxicity of
antineoplastic agents |
| 243 |
6,066,645 |
Formulations and methods of reducing toxicity of
antineoplastic agents |
| 244 |
6,057,361 |
Formulations and methods of reducing toxicity of
antineoplastic agents |
| 245 |
6,051,563 |
Methods for the administration of amifostine and
related compounds |
| 246 |
6,048,849 |
Formulations and methods of reducing toxicity of
antineoplastic agents |
| 247 |
6,046,234 |
Formulations and methods of reducing toxicity of
antineoplastic agents |
| 248 |
6,046,159 |
Formulations and methods of reducing toxicity of
antineoplastic agents |
| 249 |
6,043,249 |
Formulations and methods of reducing toxicity of
antineoplastic agents |
| 250 |
6,040,312 |
Formulations and methods of reducing toxicity of
antineoplastic agents |
|
|
